Discovery of potent, highly selective and orally efficacious SMARCA2 degraders

被引：0
|
作者：
Leng, Lingying
Yang, Lin
Tu, Wenbin
Rej, Rohan
Allu, Srinivasa Rao
Huang, Liyue
Jiang, Wei
Wang, Yu
Stuckey, Jeanne
Sarkari, Farzad R.
Wang, Meilin
Wang, Lu
Wen, Bo
Sun, Duxin
Wang, Shaomeng
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-4506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4506
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Preclinical characterization of PRT3789, a potent and selective SMARCA2 targeted degrader
    Hulse, Michael
    Agarwal, Anjana
    Wang, Min
    Carter, Jack
    Sivakumar, Monisha
    Vidal, Brian
    Brown, Justin
    Moore, Andrew
    Grego, Alexander
    Bhagwat, Neha
    Rager, Joseph
    Lu, Liang
    Basch, Corey
    Bersch, Klare
    Dai, Chaofeng
    Pitis, Philip
    Combs, Andrew
    Ruggeri, Bruce
    Vaddi, Kris
    Scherle, Peggy
    Ito, Koichi
    CANCER RESEARCH, 2022, 82 (12)
  • [32] Discovery and characterization of potent, selective CBP degraders
    La Bonte, Laura
    Sappal, Darshan
    CANCER RESEARCH, 2023, 83 (07)
  • [33] Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression
    Zhou, Haibin
    Wu, Dimin
    Bai, Longchuan
    Acharyya, Ranjan K.
    Metwally, Hoda
    McEachern, Donna
    Wen, Bo
    Sun, Duxin
    Wang, Shaomeng
    CANCER RESEARCH, 2024, 84 (06)
  • [34] SMARCA2 (BRM) degraders promotes differentiation and inhibit proliferation in AML models
    Agarwal, Anjana
    Osinubi, Olusola Peace
    Vykuntam, Komali
    Fultang, Norman
    Bhagwat, Neha
    Heiser, Diane
    Vaddi, Kris
    Ito, Koichi
    Scherle, Peggy
    CANCER RESEARCH, 2023, 83 (07)
  • [35] Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers
    Ito, Koichi
    Hulse, Michael
    Agarwal, Anjana
    Carter, Jack
    Sivakumar, Monisha
    Vykuntam, Komali
    Wang, Min
    Cowart, Miles
    Cote, Joy
    -MacDonald, William Gowen
    Torres, Brian Vidal
    Kurian, Justin
    Bhagwat, Neha
    Fultang, Norman
    Grego, Alexander
    Moore, Andrew
    Schwab, Ashley
    Burtell, Jessica
    Osinubi, Olusola Peace
    Spruance, Jacob
    Lu, Liang
    Pitis, Philip
    Basch, Corey
    Bersch, Klare
    Dai, Chaofeng
    Leal, Raul
    Shvartsbart, Artem
    Cao, Ganfeng
    Shen, Bo
    Wen, Patrick
    Rager, Joseph
    Kuskovsky, Ross
    Landman, Bob
    Emm, Tom
    Ruepp, Stefan
    Qin, Chunhua
    Paris, Gina
    Xavier, Jennifer
    Chiaverelli, Rachel
    Lee, Sang Hyun
    Geeganage, Sandy
    Lin, Hong
    Heiser, Diane
    Ruggeri, Bruce
    Babbar, Naveen
    Combs, Andrew
    Scherle, Peggy
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [36] Discovery of Highly Potent, Selective, and Efficacious Small Molecule Inhibitors of ERK1/2
    Ren, Li
    Grina, Jonas
    Moreno, David
    Blake, James F.
    Gaudino, John J.
    Garrey, Rustam
    Metcalf, Andrew T.
    Burkard, Michael
    Martinson, Matthew
    Rasor, Kevin
    Chen, Huifen
    Dean, Brian
    Gould, Stephen E.
    Pacheco, Patricia
    Shahidi-Latham, Sheerin
    Yin, Jianping
    West, Kristina
    Wang, Weiru
    Moffat, John G.
    Schwarz, Jacob B.
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (04) : 1976 - 1991
  • [37] Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist
    Eastwood, Paul
    Esteve, Cristina
    Gonzalez, Jacob
    Fonquerna, Silvia
    Aiguade, Josep
    Carranco, Ines
    Domenech, Teresa
    Aparici, Monica
    Miralpeix, Montserrat
    Alberti, Joan
    Cordoba, Monica
    Fernandez, Raquel
    Pont, Merce
    Godessart, Nuria
    Prats, Neus
    Isabel Loza, Maria
    Isabel Cadavid, Maria
    Nueda, Arsenio
    Vidal, Bernat
    ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (03): : 213 - 218
  • [38] Discovery of a highly potent and in vivo efficacious Bcl-xL selective inhibitor
    Tao, Zhi-Fu
    Wang, Le
    Nimmer, Paul M.
    Boghaert, Erwin R.
    Chen, Jun
    Hasvold, Lisa A.
    Jin, Sha
    Kovar, Peter J.
    Mitten, Michael J.
    Oleksijew, Anatol
    Park, Chang H.
    Petros, Andrew M.
    Phillips, Darren C.
    Smith, Morey
    Tahir, Stephen X.
    Tse, Chris
    Wang, Xilu
    Xiao, Yu
    Zhang, Haichao
    Deshayes, Kurt
    Fairbrother, Wayne J.
    Flygare, John A.
    Hymowitz, Sarah G.
    Koehler, Michael
    Ndubaku, Chudi
    Rawson, Tom
    Zobel, Kerry
    Colman, Peter M.
    Czabotar, Peter E.
    Huang, David C. S.
    Lessene, Guillaume
    Sleebs, Brad E.
    Watson, Keith G.
    Leverson, Joel D.
    Elmore, Steven W.
    Souers, Andrew J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [39] Discovery of selective BRM ( SMARCA2) ATPase inhibitors for the treatment of BRG1 (SMARCA4) mutant cancers
    Lee, Janice Y.
    Brooks, Nathan
    Antonakos, Brandon
    Perria, Bryan
    Langan, Candace
    Jones, Bonita D.
    Flack, Robert Stephen
    Li, Zhifang
    Terry, David
    Wallace, Ross
    Bondi, Robert
    Sis, Gereint
    Baracani, Ronee
    McVean, Maralee
    Kolakowski, Gabrielle
    Osimboni, Dayo
    Wilson, Kevin
    CANCER RESEARCH, 2024, 84 (06)
  • [40] Identification of a potent, orally-available SMARCA2/4 inhibitor with in vitro and in vivo activity in preclinical models of SMARCA4-mutant NSCLC
    Drew, Allison E.
    Jacques, Suzanne L.
    Eichinger, Lindsey W.
    Pantano, Chloe
    Motwani, Vinny
    Tang, Cuyue
    Farrow, Neil
    Brach, Dorothy
    Howe, Selene
    Raimondi, Alejandra
    Dransfield, Daniel T.
    Duncan, Kenneth W.
    Stickland, Kim
    Huang, Liyue
    Lampe, John
    CANCER RESEARCH, 2020, 80 (16)
12345